Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

被引:0
作者
Lumei Kang
Yuyang Tian
Shilin Xu
Hongping Chen
机构
[1] Medical College,Department of Animal Science
[2] Nanchang University,Department of Histology and Embryology, Medical College
[3] Nanchang University,Jiangxi Key Laboratory of Experimental Animals
[4] Nanchang University,undefined
来源
Journal of Neurology | 2021年 / 268卷
关键词
Oxaliplatin; Neuropathy; Clinical features; Prevention and treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of OXA. OIPN can be divided into acute and chronic types according to clinical features and different mechanisms. The main clinical features of acute OIPN are cold-sensitive sensory symptoms and neuropathic pain in limbs. In addition to the above symptoms, chronic OIPN also produces autonomic nerve dysfunction. The most important mechanism involved in acute OIPN is the alteration of voltage-gated Na + channels, and nuclear DNA damage in chronic OIPN. There are some methods like reducing exposure to cold, calcium and magnesium salts, amifostine could be beneficial in acute OIPN prevention and dose modification, changing in schedule glutathione, duloxetine, selective serotonin reuptake inhibitors, carbonic anhydrase inhibitor in chronic OIPN prevention. Recent updates are provided in this article in relation to the clinical features, potential mechanisms, prevention and treatment of OIPN.
引用
收藏
页码:3269 / 3282
页数:13
相关论文
共 308 条
[1]  
Freddie B(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Jacques F(2017)The role of systemic therapy in resectable gastric and gastro-oesophageal junction cancer Curr Treat Options Oncol 18 69-108
[3]  
Isabelle S(2016)S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial Lancet Oncol 17 99-5768
[4]  
Cartwright E(2017)Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer Clin Cancer Res 23 5757-34831
[5]  
Cunningham D(2016)Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: a meta-analysis of randomized controlled trials Oncotarget 7 34824-1355
[6]  
Hironaka S(2016)Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy Oncol Rep 35 1349-241
[7]  
Sugimoto N(2016)The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis J Chemother 28 235-715
[8]  
Yamaguchi K(2014)A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy Cancer Treat Rev 40 701-3116
[9]  
Dolan ME(2009)Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109-262
[10]  
El CO(2013)The complexity of adverse side-effects to biological agents J Crohns Colitis 7 257-514